Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse

Experimental Physiology

Volumn 98, Issue 3, 2013, Pages 734-745

  Toldo, Stefano ^a   Mezzaroma, Eleonora ^a   Van Tassell, Benjamin W ^a   Farkas, Daniela ^a   Marchetti, Carlo ^a   Voelkel, Norbert F ^a   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1BETA;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; ENZYME METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; INFLAMMATION; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; SHAM PROCEDURE; SYSTOLIC DYSFUNCTION;

EID: 84874075401     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.069831     Document Type: Article

References (38)

1. Abbate A (2012). The heart on fire: inflammasome and cardiomyopathy. Exp Physiol 000, 000-000.
2. Abbate A, Biondi-Zoccai GG & Baldi A (2002a). Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol 193, 145-153.
3. Abbate A, Biondi-Zoccai GG, Bussani R, Dobrina A, Camilot D, Feroce F, Rossiello R, Baldi F, Silvestri F, Biasucci LM & Baldi A (2003). Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 41, 753-760.
4. Abbate A, Bussani R, Biondi-Zoccai GG, Rossiello R, Silvestri F, Baldi F, Biasucci LM & Baldi A (2002b). Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at postmortem examination in humans late after an acute myocardial infarction. Circulation 106, 1051-1054.
5. Abbate A, Bussani R, Biondi-Zoccai GG, Santini D, Petrolini A, De Giorgio F, Vasaturo F, Scarpa S, Severino A, Liuzzo G, Leone AM, Baldi F, Sinagra G, Silvestri F, Vetrovec GW, Crea F, Biasucci LM & Baldi A (2005). Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J 26, 2039-2045.
6. Abbate A, Kontos MC & Biondi-Zoccai GG (2008a). No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J 29, 1795-1797.
7. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA & Vetrovec GW (2010a). Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 105, 1371-1377.e1.
8. Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E & Dobrina A (2011). Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One 6, e27923.
9. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, Biondi-Zoccai GG, Houser JE, Qureshi IZ, Ownby ED, Gustini E, Biasucci LM, Severino A, Capogrossi MC, Vetrovec GW, Crea F, Baldi A, Kukreja RC & Dobrina A (2008b). Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670-2683.
10. Abbate A, Van Tassell BW & Biondi-Zoccai GG (2012). Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. Biodrugs 26, 217-233.
11. Abbate A, Van Tassell BW, Seropian IM, Toldo S, Robati R, Varma A, Salloum FN, Smithson L & Dinarello CA (2010b). Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 12, 319-322.
12. Anversa P, Olivetti G & Capasso JM (1991). Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 68, 7D-16D.
13. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, Wright JR, Macdonald JA, Lees-Miller JP, Roach D, Semeniuk LM & Duff HJ (2012). The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp Physiol 000, 000-000.
14. Broberg CS, Pantely GA, Barber BJ, Mack GK, Lee K, Thigpen T, Davis LE, Sahn D & Hohimer AR (2003). Validation of the myocardial performance index by echocardiography in mice: a noninvasive measure of left ventricular function. J Am Soc Echocardiogr 16, 814-823.
15. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A & Frangogiannis NG (2008). Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173, 57-67.
16. Clausen F, Hånell A, Björk M, Hillered L, Mir AK, Gram H & Marklund N (2009). Neutralization of interleukin-1β modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice. Eur J Neurosci 30, 385-396.
17. Dinarello CA (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732.
18. Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, Cannon JG & Libby P (1987). Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 139, 1902-1910.
19. Franchi L, Eigenbrod T, Muñoz-Planillo R & Nuñez G (2009). The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10, 241-247.
20. Frangogiannis NG (2012). Regulation of the inflammatory response in cardiac repair. Circ Res 110, 159-173.
21. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R, Tracey D, Allen H, Lee RT & Kelly RA (2003). Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 35, 685-694.
22. Gardin JM, Adams DB, Douglas PS, Feigenbaum H, Forst DH, Fraser AG, Grayburn PA, Katz AS, Keller AM, Kerber RE, Khandheria BK, Klein AL, Lang RM, Pierard LA, Quinones MA & Schnittger I (2002). Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr 15, 275-290.
23. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Miyamoto T, Touma M & Sasayama S (2001). Neutralization of interleukin-1β in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 38, 1546-1553.
24. Ing DJ, Zang J, Dzau VJ, Webster KA & Bishopric NH (1999). Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 84, 21-33.
25. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S & Ikeda U (2011). Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123, 594-604.
26. Merkle S, Frantz S, Schön MP, Bauersachs J, Buitrago M, Frost RJ, Schmitteckert EM, Lohse MJ & Engelhardt S (2007). A role for caspase-1 in heart failure. Circ Res 100, 645-653.
27. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF & Abbate A (2011). The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 108, 19725-19730.
28. Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H & Bartfai T (2008). Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44, 141-148.
29. Patten RD, Aronovitz MJ, Deras-Mejia L, Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME & Konstam MA (1998). Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol Heart Circ Physiol 274, H1812-H1820.
30. Pfeffer MA & Braunwald E (1990). Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81, 1161-1172.
31. Ridker PM, Thuren T, Zalewski A & Libby P (2011). Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162, 597-605.
32. Seropian IM, Abbate A, Toldo S, Harrington J, Smithson L, Ockaili R, Mezzaroma E, Damilano F, Hirsch E & Van Tassell BW (2010). Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3Kγ) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice. J Cardiovasc Pharmacol 56, 651-658.
33. Strowig T, Henao-Mejia J, Elinav E & Flavell R (2012). Inflammasomes in health and disease. Nature 481, 278-286.
34. Stutz A, Golenbock DT & Latz E (2009). Inflammasomes: too big to miss. J Clin Invest 119, 3502-3511.
35. Syed F, Diwan A & Hahn HS (2005). Murine echocardiography: a practical approach for phenotyping genetically manipulated and surgically modeled mice. J Am Soc Echocardiogr 18, 982-990.
36. Toldo S, Bogaard HJ, Van Tassell BW, Mezzaroma E, Seropian IM, Robati R, Salloum FN, Voelkel NF & Abbate A (2011). Right ventricular dysfunction following acute myocardial infarction in the absence of pulmonary hypertension in the mouse. PLoS One 6, e18102.
37. Van Tassell BW, Seropian IM, Toldo S, Salloum FN, Smithson L, Varma A, Hoke NN, Gelwix C, Chau V & Abbate A (2010a). Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J Cardiovasc Pharmacol 55, 385-390.
38. Van Tassell BW, Varma A, Salloum FN, Das A, Seropian IM, Toldo S, Smithson L, Hoke NN, Chau VQ, Robati R & Abbate A (2010b). Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J Cardiovasc Pharmacol 55, 117-122.